Cancer-Associated Thrombosis and Bleeding Risk in Gastrointestinal Malignancies with Apixaban and Rivaroxaban Compared to Low Molecular Weight Heparin

被引：1
|
作者：
Houghton, Damon E. [1 ]
Bott-Kitslaar, Dalene M. [1 ]
Vargas, Emily [2 ]
Hodge, David O. [2 ]
Lang, Teresa R. [3 ]
Peterson, Lisa [4 ]
Casanegra, Ana I. [1 ]
McBane, Robert D. [1 ]
Wysokinski, Waldemar E. [1 ]
Froehling, David A. [3 ]
机构：
[1] Mayo Clin, Dept Cardiovasc Dis, Gonda Vasc Ctr, Thrombophilia Clin, Rochester, MN USA
[2] Mayo Clin, Dept Hlth Sci Res, Jacksonville, FL 32224 USA
[3] Gonda Vasc Ctr, Dept Cardiovasc Dis, Thrombophilia Clin, Rochester, MN USA
[4] Mayo Clin, Dept Cardiovasc Dis, Gonda Vasc Ctr, Thrombophilia Clin,Mayo Clin Rochester, Rochester, MN USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-114185
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
362
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Bleeding in Patients Receiving Low-Molecular-Weight Heparin for Cancer-Associated Thrombosis
    Chai-Adisaksopha, Chatree
    Cheah, Matthew
    AlKindi, Said Y.
    Iorio, Alfonso
    Crowther, Mark A.
    Linkins, Lori Ann
    BLOOD, 2015, 126 (23)
  • [2] Effectiveness and safety of rivaroxaban compared with low-molecular-weight heparin in cancer-associated thromboembolism
    Costa, Olivia S.
    Kohn, Christine G.
    Kuderer, Nicole M.
    Lyman, Gary H.
    Bunz, Thomas J.
    Coleman, Craig, I
    BLOOD ADVANCES, 2020, 4 (17) : 4045 - 4051
  • [3] Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism
    Coleman, Craig I.
    Caroti, Kimberly Snow
    Abdelgawwad, Khaled
    Psaroudakis, George
    Fatoba, Samuel
    Rivera, Marcela
    Schaefer, Bernhard
    Brobert, Gunnar
    Khorana, Alok A.
    Becattini, Cecilia
    Lee, Agnes Y. Y.
    Ekbom, Anders
    Carrier, Marc
    Brescia, Christopher
    Cohen, Alexander T.
    JACC: CARDIOONCOLOGY, 2023, 5 (02): : 189 - 200
  • [4] Comparison of Rivaroxaban and Low Molecular Weight Heparin in the Treatment of Cancer-Associated Venous Thromboembolism
    Coleman, Craig, I
    Caroti, Kimberly Snow
    Abdelgawwad, Khaled
    Psaroudakis, George
    Rivera, Marcela
    Brobert, Gunnar
    Cohen, Alexander T.
    Khorana, Alok A.
    Becattini, Cecilia
    Lee, Agnes Y.
    Ekbom, Anders
    Carrier, Marc
    BLOOD, 2022, 140 : 11368 - 11369
  • [5] The Net Clinical Benefit of Rivaroxaban Compared to Low-Molecular-Weight Heparin in the Treatment of Cancer-Associated Thrombosis: Systematic Review and Meta-Analysis
    Mohamed, Mouhand F. H.
    ElShafei, Mohamad Nabil
    Ahmed, Mohamed Badie
    Abdalla, Lina O.
    Ahmed, Israa
    Elzouki, Abdel-Naser
    Danjuma, Mohammed ibn-mas'ud
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2021, 27
  • [6] Reduced Emergency Room Utilization for Initiation of Anticoagulation with Rivaroxaban Versus Low Molecular Weight Heparin for Treatment of Cancer-Associated Thrombosis
    Soff, Aaron P.
    Dong, Judy
    Dong, Aiqi
    Devlin, Sean
    Mantha, Simon
    Parameswaran, Rekha
    Soff, Gerald A.
    BLOOD, 2015, 126 (23)
  • [7] Low molecular weight heparin versus rivaroxaban in the treatment of venous thromboembolism in gastrointestinal malignancies
    Choe, Hannah K.
    De Sancho, Maria T.
    Kim, Sunnie S.
    Dai, Tong
    Shah, Manish A.
    BLOOD COAGULATION & FIBRINOLYSIS, 2018, 29 (02) : 227 - 230
  • [8] Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis
    Ihaddadene, Ryma
    Le Gal, Gregoire
    Delluc, Aurelien
    Carrier, Marc
    THROMBOSIS RESEARCH, 2014, 134 (01) : 93 - 95
  • [9] Rivaroxaban versus Apixaban for Treatment of Cancer-Associated Venous Thromboembolism in Patients at Lower Risk of Bleeding
    Caroti, Kimberly Snow
    Becattini, Cecilia
    Carrier, Marc
    Cohen, Alexander T.
    Ekbom, Anders
    Khorana, Alok A.
    Lee, Agnes Y. Y.
    Brescia, Christopher
    Abdelgawwad, Khaled
    Psaroudakis, George
    Rivera, Marcela
    Schaefer, Bernhard
    Brobert, Gunnar
    Coleman, Craig I.
    TH OPEN, 2023, 07 (03) : e206 - e216
  • [10] Evaluation of bleeding risk between apixaban and rivaroxaban in patients with gastrointestinal cancer
    Gundersen, Parker
    Basilio, Alexa
    Draper, Amber
    Tiao, Emily
    Abousaud, Marin Ibrahim
    Gbolahan, Olumide B.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345